Serum soluble L-selectin in childhood acute lymphoblastic leukemia.
BACKGROUND
Determination of the serum level of soluble (s)L-selectin has been advocated for monitoring patient response to treatment in leukemia. The aim of the present study was to find out whether serum levels of sL-selectin correlated with treatment for acute lymphoblastic leukemia (ALL) in children.


RESULTS
Serum samples were obtained from 30 children with ALL, either newly diagnosed during induction therapy, in remission, in maintenance therapy, at the end of treatment or after relapse. Levels of sL-selectin were assayed in the serum of children during the clinical course of ALL using the sandwich enzyme-linked immunoabsorbent assay. Serum sL-selectin concentrations decreased significantly from diagnosis to the end of intensive chemotherapy in children with ALL and increased in the time of relapse.


CONCLUSIONS
These results suggest that monitoring of sL-selectin may be useful for evaluating leukemia activity.
Olejnik
I
I
Department of Childrens' Haematology and Chemotherapy, Silesian School of Medicine, Zabrze, Poland. olejnik@silesia.pik-net.pl
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D016903:Drug Monitoring / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D019041:L-Selectin / Q000097:blood*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D012008:Recurrence; D012074:Remission Induction
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019041:L-Selectin